Adjuvant adoptive immunotherapy tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients

Cancer Immunology Immunotherapy

Volumn 46, Issue 4, 1998, Pages 185-193

  Ridolfi, Ruggero ^a   Flamini, Emanuela ^a   Riccobon, Angela ^a   De Paola, Franca ^b   Maltoni, Roberta ^a   Gardini, Andrea ^b   Ridolfi, Laura ^b   Medri, Laura ^a   Poletti, Giovanni ^a   Amadori, Dino ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

chain p56(lck); Adoptive immunotherapy; Interleukin 2; Tumour infiltrating lymphocytes

Indexed keywords

INTERLEUKIN 2;

ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DISEASE CLASSIFICATION; HUMAN; IMMUNOTHERAPY; KIDNEY CANCER; MASTECTOMY; MELANOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SEIZURE;

ADOLESCENT; ADULT; AGED; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 7144254435     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050477     Document Type: Article

References (49)

1. Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA (1991) Lysis of autologous melanoma cells by tumour infiltrating lymphocytes: associatios with clinical response. J Natl Cancer Inst 83:932
2. Arienti F, Belli F, Rivoltini L, Gambacorti-Passerini C, Furlan L, Mascheroni L, Prada A, Rizzi M, Marchesi E, Vaglini M, Parmiani G, Cascinelli N (1993) Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumour-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother. 36:315
3. Atzpodien J, Korfer A, Palmer PA, Franks CR, Poliwoda M, Kirchner M (1990) Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and Interferon-Alpha. Ann Oncol 1:377
4. Busch E, Kemeny MM (1995): Colorectal cancer: hepatic-directed therapy the role of surgery, regional chemotherapy, and novel modalities. Sem Oncol 22:494
5. Caligiuri MA (1993) Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol 20:3
6. Cole DJ, Taubernberger JK, Pockay BA Yannelli JR, Carter C, Carrasquillo J, Leitman S, Steinberg SM, Rosenberg SA, Yang YC (1994) Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumour infiltrating lymphocytes. Cancer Immunol Immunother 38:299
7. Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, Yannelli JR, Maleckar Jr, Sferruzza A, Arnold J, West WH (1991) Continuous interleukin-2 and tumour-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 68:1
8. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R (1993) Impatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71:2358
9. Figlin R, Mulders P, Gitlitz B, Belldegrun A (1997) Cellular therapy of renal carcinoma past, present, future. Eur J Cancer 33 |Suppl 5|:28
10. lck in T cells infiltrating human renal cell carcinoma. Cancer Res 5613
11. Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S, Platsoucas CD (1994) Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumour infiltrating lymphocytes and low-dose recombinant Intcrleukin-2: a pilot trial. J Immunother 16:198
12. Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K (1995) Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumour-infiltrating lymphocytes Clin Cancer Res 1:501
13. Gansbacher B (1994) Clinical application of immunostimulatory gene transfer. Eur J Cancer 30:1187
14. Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ (1995) Adoptive inimunotherapy with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13:1939
15. Ikarashi H, Fujita K, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K (1994) Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumour-infiltrating lymophocytes. Cancer Res 54:190
16. Janssen RAJ, Mulder NH, The TH, De Leij L (1994) The immunobiological effects of interleukin-2 in vivo. Cancer Immunol Immunother 39:207
17. Jatzko GR, Lisborg PH, Stettner HM, Klimpfinger MH (1995) Hepatic resection for metastases from colorectal carcinoma. A survival analysis. Eur J Cancer 31:41
18. Karp DD, Atkins MB (1996): Adoptive immunotherapy for Non-small Cell Lung Carcinoma. Cancer 78:195
19. Linehan WM, Shipley WN, Longo DL (1989) Cancer of the kidney and ureter. In: De Vita VT, Hellman S, Rosenberg SA (eds). Cancer principles and practice of oncology. Lippincott, Philadelphia 31:979
20. Liu C-C, Walsh CM, Young JD-E (1995) Perform: structure and function. Immunol Today 16:194
21. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumour- infiltrating. hut mucosal and perpheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765
22. Merrouche Y, Negrier S, Bain C, Combaret V, Mercatello A, Coronel B, Moskovtchenko JF, Tolstoshev P, Moen R, Philip T, Favrot MC (1995) Clinical application of retroviral gene transfer in oncology: results of a French study with tumour-infiltrating-lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 13:410
23. Mertens WC, Banerjee D, Al-Mutter N, Stitt L, Bramwell VHC, Lala PK (1995) High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumouricidal function and lymphocyte subsets. Cancer Immunol Immunother 41:271
24. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
25. Nakagomi HX, Peterson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL Vivier E, Anderson P, Kiessling R (1993) Decreased expression of the signal-transducing ζ-chains in tumour-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610
26. Olencki T, Finke J, Lorenzi V, Rayman P, Budd GT, Murthy S, Klein E, Tubbs R, McLain D, Bukowski RM (1994) Adoptive immunotherapy (AIT) for renal cell carcinoma (RCC) tumour infiltrating lymphocytes (TILs) cultured in vitro with rIL-2, rhIL-4, and autologous tumour: a phase II trial. Proc Annu Meet Am Soc Clin Oncol 13:A762
27. Overett TK, Shiu MH (1985) Surgical treatment of distant metastatic melanoma. Cancer 56:1222
28. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R, Francks CR (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant Interleukin-2. Ann Oncol 3:475
29. Peace DY, Cheever MA (1989) Toxicity and therapeutic efficacy of high-dose interleukin-2. J Exp Med 169:161
30. Pierce W, Belldegrun A, deKernion J, Figlin R (1994) Immunotherapy of patients with metastatic renal cell carcinoma (RCCa) using tumour infiltrating lymphocytes (TIL) in combination with an outpatient regimen of Interleukin-2 (IL-2) with or without interferon-alpha (IFN-alpha): UCLA Kidney Cancer Program. Proc Annu Meet Am Soc Clin Oncol 13:A736
31. Pockay BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, Carasquillo SM, Steiberg JA, Rosenberg SA, Yang JC (1994) Localization of 111-indium-labeled tumour infiltrating lymphopcytes to tumour in patients receiving adoptive immunotherapy. Cancer 73:1731
32. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL (1996) Expression and activity of signaling molecules in T lymphocytes obteined from patients with metastatic melanoma before and after interleukin 2 therapy Clin Cancer Res 2:1263
33. Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G, Spessa E, Ponte M, Bruzzi P, Melioli G (1996) A randomized trial of adoptive immunotherapy with tumour-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78:244
34. Ravaud A, Legrand E, Delaunat MM, Bussieres E, Coulon V, Cany L, Huest S, Verdier D, Kind M, Chomy F, Bui BN, Gualde N (1995) A phase I trial of repeated tumour infiltrating lymphocyte (TIL) infusion in metastatic melanoma. Br J Cancer 71:331
35. Ridolfi R, Maltoni R, Flamini E, Riccobon A, De Paola F, Amadori D (1996) TIL cultures from 60 solid tumours and reinfusion with IL-2 in 26 patients. Proc Am Soc Clin Oncol Meet: 1045
36. Rosenberg SA, Lotze TL, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474
37. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White de Steinberg SM (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjugation with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622
38. Rosenberg SA, Yannelli JR, Yang JC, Topalian L, Schwartzentruber J, Weber S, Parkinson R, Seipp A, Einhorn HD, White E (1994) Treatment of patients with metastatic melanoma with autologous tumour infiltrating lymphocytes and Interleukin-2. J Natl Cancer Inst 86:1159
39. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JD, Steinberg SM, Rosenberg SA and Topalian SL (1994) In vitro predictors of therapeutic response in melanoma patients receiving tumour-infiltrating lymphocytes and Interleukin-2. J Clin Oncol 12:1475
40. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells-A mechanism of immune evasion? Nature Med 12:1361
41. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D'Enghien CD, Lee R, Debre B, Fridman WH (1995) Variable expression of CD3-zeta chain in tumour infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 63:205
42. Topalian SL, Rosenberg SA (1989) Tumour specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142:3714
43. Topalian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of human tumour infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127
44. Vose BM, Moore M (1985) Human tumour-infiltrating lymphocytes: a marker of host response. Semin Hematol 22:27
45. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Costant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898
46. Whiteside TL (1992) Tumour infiltrating lymphocytes as antitumour effector cells. Biotherapy 5:47
47. Whiteside TL, Parmiani G (1994) Tumour infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 39:15
48. Xu X, Xu L, Ding S, Wu M, Tang Z, Fu W, Ni Q (1995) Treatment of 23 patients with advanced gastric cancer by intravenously transfer of autologous tumour-infiltrating lymphocytes combined with rIL-2. Chin Med Sci J 10:185
49. Zier K, Gansbacher B, Salvadori S (1996) Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 39:45